Article information
Full text is only aviable in PDF
Bibliografía
[1.]
M. Conti, J. Beavo.
Biochemistry and hysiology of cyclic nucleotide phosphodiesterases: Essential components in Cyclic nucleotide signaling.
Annu Rev Biochem, 76 (2007), pp. 481-511
[2.]
K. Omori, J. Kotera.
Overview of PDEs and their regulation.
Circ Res, 100 (2007), pp. 309-327
[3.]
D. Halpin.
ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
International J of COPD, 3 (2008), pp. 543-561
[4.]
E. Gordon, S.C. Lazarus.
Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
J Allergy Clin Immunol, 124 (2009), pp. 873-880
[5.]
J. Bourbeau, M. Johnson.
New and controversial therapies for chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 6 (2009), pp. 553-554
[6.]
R.A. Stockley, D. Mannino, P.J. Barnes.
Burden and pathogenesis of chronic obstructive pulmonary disease.
Proc Am Thorac Soc, 6 (2009), pp. 524-526
[7.]
P.J. Barnes, B.R. Celli.
Systemic manifestations and comorbidities of COPD.
Eur Respir J, 33 (2009), pp. 1165-1185
[8.]
L. Pagès, Gavaldà A., M.D. Lehner.
PDE4 inhibitors: a review of current developments (2005-2009).
Expert Opin Ther Pat, 19 (2009), pp. 1501-1519
[9.]
J. Cortijo, J. Bou, J. Beleta, I. Cardelus, J. Llenas, E. Morcillo, et al.
Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
Br J Pharmacol, 108 (1993), pp. 562-568
[10.]
J. Cortijo, V. Villagrasa, C. Navarrete, C. Sanz, L. Berto, A. Michel, et al.
Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.
Br J Pharmacol, 119 (1996), pp. 99-106
[11.]
J. Cortijo, M. Marti-Cabrera, L. Berto, F. Anton, E. Carrasco, M. Grau, et al.
Pharmacological activity of PF-904 in guinea pig in vivo, and on human bronchus and neutrophils in vitro.
Eur J Pharmacol, 333 (1997), pp. 69-78
[12.]
J. Cortijo, R. Pons, F. Dasi, N. Marin, M. Martinez-Losa, C. Advenier, et al.
Bronchodilator and anti-inflammatory activities of SCA40: studies in human isolated bronchus, human eosinophils, and in the guinea-pig in vivo.
Naunyn Schmiedeberg's Arch Pharmacol, 356 (1997), pp. 806-814
[13.]
J. Cortijo, E. Naline, J.L. Ortiz, L. Berto, V. Girard, M. Malbezin, et al.
Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: functional and biochemical study.
Eur J Pharmacol, 341 (1998), pp. 79-86
[14.]
J. Cortijo, V. Villagrasa, R. Pons, L. Berto, M. Martí-Cabrera, M. Martinez-Losa, et al.
Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.
Br J Pharmacol, 127 (1999), pp. 1641-1651
[15.]
M.J. Sanz, J. Cortijo, E.J. Morcillo.
PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Pharmacol Ther, 106 (2005), pp. 269-297
[16.]
M.J. Sanz, J. Cortijo, M.A. Taha, M. Cerda-Nicolas, E. Schatton, B. Burgbacher, et al.
Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.
Br J Pharmacol, 152 (2007), pp. 481-492
[17.]
T.D. Bethke, G.M. Bohmer, R. Hermann, B. Hauns, R. Fux, K. Morike, et al.
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
J Clin Pharmacol, 47 (2007), pp. 26-36
[18.]
A. Hatzelmann, C. Schudt.
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
J Pharmacol Exp Ther, 297 (2001), pp. 267-279
[19.]
A. Hatzelmann, E.J. Morcillo, G. Lungarella, S. Adnot, S. Sanjar, Beume.
The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Pulm Pharmacol Ther, 23 (2010), pp. 235-256
[20.]
J.L. Ortiz, J. Cortijo, J.M. Valles, E.J. Morcillo.
Rolipram inhibits PAF-induced airway microvascular leakage in guinea-pig: a comparison with milrinone and theophylline.
Fund Clin Pharmacol, 6 (1992), pp. 247-249
[21.]
J.L. Ortiz, J.M. Valles, M. Marti-Cabrera, J. Cortijo, EJ. Morcillo.
Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.
Naunyn Schmiedeberg’s Arch Pharmacol, 353 (1996), pp. 200-206
[22.]
A. Hatzelmann, C. Schudt.
Antiinflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
J Pharmacol Exp Ther, 297 (2001), pp. 267-279
[23.]
J. Milara, J. Cortijo, M. Mata, E. Donet, M. Mauricio, E.J. Morcillo.
The PDE4 inhibitor roflumilast N-oxide partly reversed TGFβ1-induced changes in collagen I and E-cadherin expression in human airway epithelial cells.
Eur Respir J Suppl, 639s (2008), pp. P3648
[24.]
J. Cortijo, A. Iranzo, X. Milara, M. Mata, M. Cerdá-Nicolás, A. Ruiz-Saurí, et al.
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Br J Pharmacol, 156 (2009), pp. 534-544
[25.]
G. Borzone, R. Moreno, R. Urrea, M. Meneses, M. Oyarzun, C. Lisboa.
Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 163 (2001), pp. 1648-1653
[26.]
N.I. Chaudhary, A. Schnapp, J.E. Park.
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
Am J Respir Crit Care Med, 173 (2006), pp. 769-776
[27.]
A. Chaouat, R. Naeije, E. Weitzenblum.
Pulmonary hypertension in COPD.
Eur Respir J, 32 (2008), pp. 1371-1385
[28.]
M. Izikki, B. Raffestin, J. Klar, A. Hatzelmann, D. Marx, H. Tenor, et al.
Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
J Pharmacol Exp Ther, 330 (2009), pp. 54-62
[29.]
P.A. Martorana, R. Beume, M. Lucattelli, L. Wollin, G. Lungarella.
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
Am J Respir Crit Care Med, 172 (2005), pp. 848-853
[30.]
H. Tran Mori, T. Nose, K. Ishitani, S. Kasagi, S. Souma, T. Akiyoshi, et al.
Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain.
Am J Physiol Lung Cell Mol Physiol, 294 (2008), pp. L196-L204
[31.]
J.C. Fox, D. Spicer, R. Henning, B. Meshi, M.T. Shrad, JC. Hogg.
Efficacy of the PDE4 inhibitor, BAY 19-8004, in tobacco smoke models of COPD in the guinea pig.
Am J Respir Crit Care Med, 167 (2003), pp. A91
[32.]
N.A. Jones, V. Boswell-Smith, R. Lever, C.P. Page.
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.
Pulm Pharmacol Ther, 18 (2005), pp. 93-101
[33.]
Y. Kasahara, R.M. Tuder, C.D. Cool, D.A. Lynch, S.C. Flores, N.F. Voelkel.
Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema.
Am J Respir Crit Care Med, 163 (2001), pp. 737-744
[34.]
S. Namkoong, C.K. Kim, Y.L. Cho, J.H. Kim, H. Lee, K.S. Ha, et al.
Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling.
Cell Signal, 21 (2009), pp. 906-915
[35.]
R.F. Foronjy, O. Mirochnitchenko, O. Propokenko, V. Lemaitre, Y. Jia, M. Inouye, et al.
Superoxide dismutase expression attenuates cigarette smoke- or elastase-generated emphysema in mice.
Am J Respir Crit Care Med, 173 (2006), pp. 623-631
[36.]
S. Muzaffar, N. Shukla, G.D. Angelini, J.Y. Jeremy.
Roflumilast N-oxide inhibits NADPH oxidase expression and activity in human pulmonary artery smooth muscle cells.
Proc Br Pharmacol Soc, 6 (2008), pp. 027P
[37.]
J.C. Hogg, F. Chu, S. Utokaparch, R. Woods, W.M. Elliott, L. Buzatu, et al.
The nature of small-airway obstruction in chronic obstructive pulmonary disease.
N Engl J Med, 350 (2004), pp. 2645-2653
[38.]
A.G. Agusti.
COPD, a multicomponent disease: implications for management.
Respir Med, 99 (2005), pp. 670-682
[39.]
A. Wohlsen, L. Wollin, D. Marx, R. Beume.
Effect of roflumilast and other cAMP elevating agents on airway beat ciliary frequency in proximal and distal airways in rat precision cut lung slices.
Fifth International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5),
[40.]
J. Milara, J. Cortijo, M. Armengot, P. Banuls, E. Gabarda, E. Morcillo.
Effect of roflumilast, a PDE4 inhibitor on ciliary beat frequency in human nasal epithelial cells.
Eur Respir J Suppl, 639s (2008), pp. P3651
[41.]
N. Pedemonte, L. Galietta.
Stimulation of CFTR-dependent chloride secretion by roflumilast.
Eur Respir J Suppl, 644s (2008), pp. P3672
[42.]
M. Mata, B. Sarria, A. Buenestado, J. Cortijo, M. Cerda, E.J. Morcillo.
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Thorax, 60 (2005), pp. 144-152
[43.]
A. Weidenbach, C. Braun, M.D. Lehner, F. Schwoebel, R. Beume, J. Barsig.
Therapeutic effect of roflumilast on LPS- and OVA-induced gobelt cell hyperplasia in rats.
Eur Respir J Suppl, (2007), pp. E315
[44.]
J.M. Hohlfeld, K. Schoenfeld, M. Lavae-Mokhtari, F. Schaumann, M. Mueller, D. Bredenbroeker, et al.
Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.
Pulm Pharmacol Ther, 21 (2008), pp. 616-623
[45.]
D.C. Grootendorst, S.A. Gauw, R.M. Verhoosel, P.J. Sterk, J.J. Hospers, D. Bredenbroker, et al.
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Thorax, 62 (2007), pp. 1081-1087
[46.]
L.M. Fabbri, P.M. Calverley, J.L. Izquierdo-Alonso, D.S. Bundschuh, M. Brose, M.artinez, etc. M2-127 and M2-128 study groups.
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Lancet, 374 (2009), pp. 695-703
[47.]
P.M. Calverley, K.F. Rabe, U.M. Goehring, S. Kristiansen, L.M. Fabbri, F.J. Martinez, M2-124 and M2-125 study groups.
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Lancet, 374 (2009), pp. 685-694
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
